IRLAB THERAPEUTICS
IRLAB is a Swedish drug discovery and development company providing novel treatments for disorders of the brain. IRLAB is engaged in programmes targeting core dysfunctions in Parkinson’s disease and dementias. IRLAB has identified, and is currently engaged in clinical development of, two novel compounds aimed at offering improved clinical benefit for patients with Parkinson’s disease.
IRLAB THERAPEUTICS
Industry:
Health Care Therapeutics
Founded:
2013-01-01
Address:
Göteborg, Vastra Gotaland, Sweden
Country:
Sweden
Website Url:
http://www.irlab.se
Total Employee:
11+
Status:
Active
Contact:
+46 31 757 3800
Email Addresses:
[email protected]
Total Funding:
15.92 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics WordPress Google Universal Analytics Apache Wordpress Plugins Sitelinks Search Box
Current Advisors List
Current Employees Featured
Founder
Investors List
EASME - EU Executive Agency for SMEs
EASME - EU Executive Agency for SMEs investment in Grant - IRLAB Therapeutics
New Leaf Venture Partners
New Leaf Venture Partners investment in Series A - IRLAB Therapeutics
Official Site Inspections
http://www.irlab.se Semrush global rank: 4.93 M Semrush visits lastest month: 1.74 K
- Host name: 193.14.90.36
- IP address: 193.14.90.36
- Location: Sweden
- Latitude: 59.3247
- Longitude: 18.056
- Timezone: Europe/Stockholm
More informations about "IRLAB Therapeutics"
Homepage - IRLAB
Apr 25, 2025 IRLAB publishes the Annual Report for 2024. Gothenburg, Sweden, April 25, 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and …See details»
About IRLAB - IRLAB
IRLAB’s share (IRLAB A) has been traded on Nasdaq Stockholm Main Market since September 2020, a move from Nasdaq First North Premier Growth Market where the company was listed …See details»
Startsida - IRLAB
25 APRIL 2025 / REGULATORISK IRLAB publicerar årsredovisning för 2024. Göteborg, den 25 april 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett företag som upptäcker …See details»
IRLAB publishes the Annual Report for 2024 - PharmiWeb.com
Apr 25, 2025 GOTHENBURG, SWEDEN / ACCESS Newswire / April 25, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - Gothenburg, Sweden, April 25, 2025 - IRLAB …See details»
IRLAB Therapeutics AB | Aktiebolag | Info & Löner - Bolagsfakta
IRLAB Therapeutics AB – Org.nummer: 556931-4692. På Bolagsfakta.se hittar du kontakt-och företagsinformation, nyckeltal, lön till VD & styrelse m.m.See details»
IRLAB THERAPEUTICS Q4.2024 Year-end report January– …
IRLAB has validated the R&D and business strategy by: • Discovering and developing investigational drugs from drug discovery to Phase III-ready projects. Organization positioned …See details»
IRLAB Therapeutics AB - 556931-4692 - Göteborg - Se Nyckeltal ...
Allabolag.se ger dig företagsinformation om IRLAB Therapeutics AB, 556931-4692. Hitta adress på karta, kontaktinfo, nyckeltal och befattningar.See details»
IRLAB publishes the Annual Report for 2024 - MFN.se
Apr 25, 2025 Viktor Siewertz, CFO Phone: +46 727 10 70 70 E-mail: [email protected] This information is information that IRLAB Therapeutics is obliged to make public pursuant to …See details»
IRLAB Therapeutics - Edison Group
Based in Sweden, IRLAB Therapeutics is focused on developing novel drugs for the treatment of neurodegenerative diseases utilising its ISP technology platform. Its two lead assets, …See details»
IRLAB has received approval from the Swedish Medical Products …
May 6, 2024 MJFF is the world's largest non-profit funder of Parkinson's disease research and the organization's support of IRL757 provides a strong external validation of the project's …See details»
Irlab Therapeutics – Wikipedia
Irlab Therapeutics AB är ett svenskt läkemedelsföretag med säte i Göteborg, som grundades 2013 och utvecklar läkemedelskandidater avsedda för behandling av Parkinsons sjukdom. …See details»
IRLAB Therapeutics - Crunchbase Company Profile & Funding
IRLAB is a Swedish drug discovery and development company providing novel treatments for disorders of the brain. IRLAB is engaged in programmes targeting core dysfunctions in …See details»
IRLAB publishes the Annual Report for 2024 | Placera.se
Gothenburg, Sweden, April 25, 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, announced …See details»
Irlab - Overview, News & Similar companies | ZoomInfo.com
May 21, 2024 Who is Irlab. IRLAB is a Swedish research and development company that focuses on developing novel treatments in Parkinson's disease. The company's most …See details»
IRLAB Therapeutics AB Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for IRLAB Therapeutics AB of Göteborg, Västra Götaland. Get the latest business insights from Dun & …See details»
IRLAB has Received Approval from the Swedish Medical ... - BioSpace
May 6, 2024 MJFF is the world’s largest non-profit funder of Parkinson’s disease research and the organization’s support of IRL757 provides a strong external validation of the project’s …See details»
IRLAB Therapeutics - LIFE SCIENCE-DAGEN
Irlab Therapeutics är ett svenskt forsknings- och läkemedelsbolag grundat i Göteborg under 2013. Verksamheten bedrivs via dotterbolaget Irlab Sweden. Forskningen är specialiserad mot …See details»
Diversity - IRLAB
IRLAB’s organization promotes an inclusive corporate culture at every level. The company, which conducts research and development operations, normally has specific expertise and education …See details»
Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement …
Jul 15, 2021 More information on www.irlab.se. Ipsen’s Forward-looking statements The forward-looking statements, objectives and targets contained herein are based on the Group’s …See details»
IRLAB publicerar årsredovisning för 2024 - IRLAB
Göteborg, den 25 april 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett företag som upptäcker och utvecklar nya behandlingar vid Parkinsons sjukdom, meddelade idag att …See details»